Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW; REgression GRowth Evaluation Statin Study Group. Boekholdt SM, et al. Among authors: agema wr. Circulation. 2003 May 20;107(19):2416-21. doi: 10.1161/01.CIR.0000068311.40161.28. Epub 2003 May 12. Circulation. 2003. PMID: 12742999 Clinical Trial.
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions.
Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van Vlijmen BJ, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: agema wr. Circulation. 2005 Oct 18;112(16):2417-25. doi: 10.1161/CIRCULATIONAHA.105.536268. Circulation. 2005. PMID: 16230497
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: agema wr. Thromb Haemost. 2005 Mar;93(3):564-9. doi: 10.1160/TH04-11-0708. Thromb Haemost. 2005. PMID: 15735811 Clinical Trial.
Tumor necrosis factor-alpha plays an important role in restenosis development.
Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, 't Hart LM, Frants RR, Quax PH, van Vlijmen BJ, Havekes LM, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: agema wr. FASEB J. 2005 Dec;19(14):1998-2004. doi: 10.1096/fj.05-4634com. FASEB J. 2005. PMID: 16319143
Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement.
Rana JS, Monraats PS, Zwinderman AH, de Maat MP, Kastelein JJ, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Rana JS, et al. Among authors: agema wr. Thromb Haemost. 2005 Oct;94(4):892-4. Thromb Haemost. 2005. PMID: 16270652 No abstract available.
20 results